Human TRAIL R1/CD261/TNFRSF10A (His & Fc Tag) recombinant protein

Human TRAIL R1/CD261/TNFRSF10A (His & Fc Tag) recombinant protein

• DataSheet
• Material Safety Data Sheets (MSDS)

Tumor necrosis factor receptor superfamily, member 10a (TRAIL R1), also known as TRAIL receptor 1 (TRAIL R1) or CD261 antigen, is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R1/CD261/TNFRSF10A serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAIL R1 can promote the activation of NF-kappa-B. TRAIL R1/CD261/TNFRSF10A induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types.

TNFRSF10A; DR4; APO2; TRAIL R1; MGC9365; TRAILR-1; TRAILR1; CD261

O00220

Human Cells

A DNA sequence encoding the human TNFRSF10A (NP_003835.2) extracellular domain (Met 1-Asn 239) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus.

Human

The recombinant human TNFRSF10A/Fc is a disulfide-linked homodimer. The reduced monomer consists of 378 amino acids and has a predicted molecular mass of 42 kDa. As a result of glycosylation, the apparent molecular mass of rh TNFRSF10A/Fc monomer migrates with an apparent molecular mass of 47 kDa in SDS-PAGE under reducing conditions.

> 98 % as determined by SDS-PAGE

1. Measured by its binding ability in a functional ELISA. Immobilized human TNFSF10 at 10 μg/ml (100 μl/well) can bind human TNFRSF10A Fc Chimera with a linear range of 0.625-20 ng/ml.
2. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED₅₀ for this effect is typically 5-20 ng/ml in the presence of 20 ng/ml Recombinant Human TRAIL/TNFSF10.